Zoetis Q3 2026 Results: Revenue Falls 1% to $2.4 Billion as US Companion Animal Business Weakens

Zoetis narrows its 2026 revenue outlook but raises adjusted EPS guidance, as international livestock growth and portfolio innovation partly offset pressure in the US companion animal market.

Zoetis’ third-quarter 2026 results point to a business navigating an uneven animal-health market. The company reported revenue of $2.4 billion, down 1%, while adjusted diluted earnings per share (EPS) rose 3% to $1.75. The headline contrast is between a weaker US companion-animal business and stronger international and livestock performance.

The company narrowed its full-year revenue guidance to $9.22–$9.32 billion and raised its adjusted EPS outlook to $6.25–$6.35. The revised outlook suggests management is placing greater emphasis on earnings delivery and operational discipline while working through pricing sensitivity, competitive pressure and generic erosion in selected companion-animal categories.

Q3 2026 financial performance: earnings resilience despite softer revenue

For the three months ended September 30, 2026, Zoetis generated $2.391 billion in revenue, compared with $2.422 billion in the corresponding quarter of 2025. Revenue declined 1% on both reported and organic operational measures.

The earnings picture was more mixed. Reported net income fell 18% to $591 million, while adjusted net income declined 5% to $720 million. Reported diluted EPS decreased 12% to $1.44, but adjusted diluted EPS increased 3% to $1.75.

The gap between reported and adjusted earnings deserves attention. Zoetis said adjusted net income excluded a net $129 million impact from purchase-accounting adjustments, acquisition- and divestiture-related costs, and certain significant items. Adjusted measures are useful for understanding management’s view of underlying performance, but they are non-GAAP measures and should be read alongside reported earnings.

The nine-month numbers add another dimension. Revenue for the first nine months of 2026 was $7.121 billion, compared with $7.094 billion a year earlier—broadly flat on a reported basis. Over the same period, companion-animal revenue declined 4%, while livestock revenue increased 11%. This reinforces the quarter’s central theme: livestock is currently providing a stronger growth engine than companion animals.

US companion-animal business is the principal pressure point

The US segment reported Q3 revenue of $1.246 billion, down 6% from $1.322 billion in Q3 2025. The decline was driven primarily by companion-animal products. US companion-animal revenue fell 8%, with Zoetis identifying three principal pressures:

• Greater price sensitivity: macroeconomic conditions are influencing pet-owner spending and willingness to pay for veterinary treatments.

• Competitive pressure in dermatology: the company is facing a more challenging competitive environment in an important companion-animal therapeutic category.

• Generic competition: generic alternatives are affecting sales in selected product areas.

This is strategically important because companion-animal medicines have been a major source of growth and innovation for the animal-health industry. Dermatology, parasiticides and chronic-pain management are particularly significant categories, supported by increasing expectations for longer-term management of pet health conditions.

The pressure is not uniform across the US business. Zoetis reported 5% growth in US livestock revenue, supported by cattle, swine and poultry. The contrast suggests that the current weakness is concentrated in parts of the companion-animal portfolio rather than reflecting a broad-based contraction across all animal-health markets.

International business delivers growth, led by livestock

The International segment generated approximately $1.1 billion in Q3 revenue, increasing 4% on both reported and organic operational bases.

International companion-animal revenue was relatively stable. Growth in parasiticides and osteoarthritis pain helped offset lower sales of key dermatology products. Livestock was the stronger contributor, with growth in cattle and fish.

The regional performance is relevant to the wider animal-health market. Livestock demand is influenced by disease prevention, herd productivity, food security, animal-protein production and the economics of commercial farming. These drivers can differ substantially from the consumer-spending factors affecting companion-animal medicines.

For Zoetis, international livestock growth provides diversification at a time when its US companion-animal franchise is under pressure. However, the company has not provided enough detail in the supplied results to attribute the international growth to individual countries or to quantify the contribution of particular livestock products.

Livestock portfolio: a key source of growth and diversification

The quarter’s species-level revenue figures provide further evidence of the shift in growth contribution.

On an organic operational basis, companion-animal revenue declined 5%, while livestock revenue increased 7%. The livestock business therefore grew sufficiently to cushion the decline in the much larger companion-animal category.

This is a notable portfolio development. Companion animals still accounted for the majority of Q3 revenue, at approximately 65%, while livestock contributed about 33%. Yet livestock delivered the stronger growth rate. The remaining revenue came from contract manufacturing and human health.

The figures also highlight why a diversified animal-health portfolio matters. A company exposed to both pet medicines and production-animal health can draw on different demand drivers, although diversification does not eliminate the effect of weakness in a major business line.

Innovation and regulatory approvals: new products across companion animals and livestock

Despite the challenging revenue environment, Zoetis reported progress across its product pipeline and regulatory portfolio. The company said it remained on track for expected 2026 product approvals, with certain approvals previously anticipated in 2027 now expected in the fourth quarter of 2026.

Convenia RTU for Dogs: US FDA approval

In October 2026, Zoetis received US Food and Drug Administration approval for Convenia RTU for Dogs, a long-acting antibacterial injection.

The approval expands the company’s canine treatment portfolio and is expected to make the product available to veterinarians in Q1 2027. The launch will be worth monitoring for its commercial contribution and adoption by veterinary practices.

Lenivia and Portela: expansion of long-acting osteoarthritis treatment

Zoetis launched Lenivia for dogs in Great Britain and received Swiss approval for Portela for cats. Both expand access to long-acting osteoarthritis pain relief, with treatment intended to last for up to three months following a single injection.

Long-acting pain-management products are strategically important in veterinary medicine because they can reduce the frequency of administration and support continuity of treatment for animals with chronic conditions. Their commercial success will depend on clinical positioning, veterinary acceptance, reimbursement or affordability considerations, and competition within the OA category.

Simparica Trio: emergency authorisation for New World screwworm

Simparica Trio received US FDA Emergency Use Authorization (EUA) for the treatment of New World screwworm infestations in dogs and puppies.

The authorisation adds to Zoetis’ wider response to the New World screwworm threat, which also includes Dectomax and Dectomax-CA1 for other at-risk species.

New World screwworm is a significant animal-health concern because its larvae infest living tissue, potentially causing severe wounds, secondary infections and, in serious cases, death. The authorisation gives veterinarians an additional product option for the specified canine use. It should not be interpreted as a general approval for every species or every type of parasitic infestation.

Other regulatory approvals

The company also reported several approvals and label expansions across markets:

The approvals span swine respiratory disease prevention, canine infectious disease protection and feline anaesthesia. Collectively, they demonstrate the breadth of Zoetis’ regulatory activity across species and geographies.

Simparica Trio research and launch of Zoetis Medical Hub

Zoetis highlighted a peer-reviewed study published in Parasites & Vectors comparing heartworm outcomes in dogs treated with Simparica Trio and NexGard Plus.

According to the company’s announcement, dogs treated with Simparica Trio had significantly lower average heartworm counts than dogs receiving NexGard Plus. At the end of the study, few dogs in the Simparica Trio group had adult heartworms.

The finding is commercially relevant because heartworm prevention is a competitive and clinically important segment of the companion-animal parasiticide market. Comparative efficacy research can influence veterinary recommendations, product differentiation and brand positioning.

However, the result should be interpreted within the study’s specific design, population, endpoints and treatment conditions. A single comparative study does not establish that one product is universally superior across all clinical settings. Veterinarians should consider the full published evidence and approved product labelling when making treatment decisions.

Zoetis has also launched the Zoetis Medical Hub, a platform intended to bring together medical expertise and peer-reviewed research. The initiative could strengthen the company’s scientific engagement with veterinarians by improving access to clinical information and product-related evidence.

Full-year 2026 guidance: revenue range narrowed, adjusted EPS raised

Zoetis has narrowed its full-year revenue guidance while raising its adjusted net income and adjusted diluted EPS outlook.

Company guidance as of November 5, 2026. Currency assumptions reflect foreign exchange rates as of October 20, 2026. The revisions contain two important messages.

First, revenue expectations have been adjusted upward at the lower end of the range. The new revenue range is $9.22–$9.32 billion, compared with $9.12–$9.32 billion previously. The upper end remains unchanged, but the lower end has increased by $100 million.

Second, profitability expectations have improved. The adjusted net income range has increased to $2.60–$2.64 billion, while adjusted diluted EPS has moved to $6.25–$6.35 from $6.15–$6.25.

The company has also lowered its expected adjusted R&D expenditure to $705–$715 million from $720–$730 million, while maintaining adjusted cost of sales at approximately 29% of revenue. The revised guidance therefore reflects not only the revenue outlook but also changes in the expected cost and earnings profile.

One distinction is important: Zoetis’ adjusted earnings guidance is being raised even though the company continues to forecast negative organic operational growth for the full year. The higher EPS range should therefore not be interpreted as evidence that underlying revenue growth has returned. It reflects management’s revised expectations for earnings, costs and other financial items.

What the results mean for the global animal-health industry

Zoetis’ Q3 performance offers several signals for animal-health companies, veterinary businesses, livestock producers and investors.

A. Companion-animal growth is facing a more demanding commercial environment

The 8% decline in US companion-animal revenue is the clearest weakness in the results. Zoetis specifically identified price sensitivity, dermatology competition and generic competition.

This suggests that even established veterinary medicine categories are not insulated from affordability pressures. Pet owners may defer treatment, seek lower-cost alternatives or become more selective about spending. For manufacturers, this increases the importance of demonstrating clinical value, maintaining veterinary confidence and differentiating branded therapies from competing products.

B. Livestock health is becoming an increasingly important earnings contributor

Livestock revenue grew 7% globally in the quarter on a reported basis and 11% over the first nine months of 2026. Growth in cattle, swine, poultry and fish contributed to the performance across the company’s markets.

The sector’s longer-term demand drivers include infectious-disease prevention, productivity improvement, biosecurity, reproductive performance and the need to protect animal-protein supply chains. These drivers create opportunities for vaccines, parasiticides, diagnostics and other veterinary products.

The results do not establish that livestock will permanently replace companion animals as Zoetis’ principal growth engine. They do, however, show that livestock is currently providing an important counterweight to weakness in parts of the pet-health business.

C. Long-acting therapies remain a strategic innovation area

The expansion of Lenivia and Portela reflects continued investment in long-acting osteoarthritis pain management. Such products can offer practical advantages in chronic disease management by reducing the frequency of treatment administration.

The category is likely to remain commercially important as veterinary medicine increasingly focuses on quality of life, mobility and long-term management of chronic conditions in ageing companion animals.

D. Regulatory execution and pipeline timing matter

Zoetis reported that two major-market approvals in 2026 were achieved ahead of expected timelines and that certain approvals previously expected in 2027 are now anticipated in Q4 2026.

Earlier-than-expected approvals can bring forward potential commercial opportunities. But regulatory milestones should be distinguished from actual sales contribution: launch timing, market access, veterinary adoption and competitive positioning determine how quickly approvals translate into revenue.

Conclusion

Livestock growth cushions companion-animal weakness, while earnings guidance improves

Zoetis’ third-quarter 2026 results show a company experiencing contrasting trends across its animal-health portfolio. Revenue declined 1% to $2.391 billion, and reported net income fell 18%. The US companion-animal business was the most significant source of pressure, with revenue down 8%, reflecting price sensitivity, dermatology competition and generic alternatives.

At the same time, livestock revenue increased 7% globally, with particularly strong growth in international livestock markets. New approvals across canine, feline and livestock products, together with progress in long-acting osteoarthritis therapies and the Simparica Trio portfolio, demonstrate continued investment in innovation.